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Abstract
Background: Although the throughput of next generation sequencing is increasing and at the same time the cost is
substantially reduced, for the majority of laboratories whole genome sequencing of large cohorts of cancer samples is still
not feasible. In addition, the low number of genomes that are being sequenced is often problematic for the downstream
interpretation of the significance of the variants. Targeted resequencing can partially circumvent this problem; by focusing
on a limited number of candidate cancer genes to sequence, more samples can be included in the screening, hence
resulting in substantial improvement of the statistical power. In this study, a successful strategy for prioritizing candidate
genes for targeted resequencing of cancer genomes is presented.
Results: Four prioritization strategies were evaluated on six different cancer types: genes were ranked using these
strategies, and the positive predictive value (PPV) or mutation rate within the top-ranked genes was compared to the
baseline mutation rate in each tumor type. Successful strategies generate gene lists in which the top is enriched for known
mutated genes, as evidenced by an increase in PPV. A clear example of such an improvement is seen in colon cancer, where
the PPV is increased by 2.3 fold compared to the baseline level when 100 top fitSNP genes are sequenced.
Conclusions: A gene prioritization strategy based on the fitSNP scores appears to be most successful in identifying mutated
cancer genes across different tumor entities, with variance of gene expression levels as a good second best.
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Introduction
Currently, cancer exome and genome sequencing is technically
possible through next generation sequencing technologies that
provide high throughput and low cost per base compared to
classical Sanger sequencing [1]. However, due to the massive
amount of sequence data generated on both coding and non-
coding genomic regions, a challenge for the identification of
disease relevant mutations or variations arises. Moreover, due to
the high overall cost of these new technologies, such a genome
wide screen is typically performed on a limited number of samples,
which reduces the statistical power of such studies. Therefore,
targeted resequencing is still being performed and remains a
relevant and valid method that can circumvent these issues [2]. By
focusing on specific candidate genes, a larger cohort of samples
can be screened, which will increase the statistical power of the
data analysis and will allow a better discrimination between driver
and passenger mutations. The subsequent reduction in the amount
of generated sequence information, often accompanied with
higher coverage depth, will significantly facilitate the handling
and interpretation of the data.
Crucially, such a targeted approach requires a method to prioritize
and rationally select suitable candidate genes to include in the
sequencing effort. This study aimed at the evaluation of four different
strategies to prioritize candidate genes for targeted resequencing of
cancer genomes.
A first approach is based on the fitSNP (functionally interpolating
single nucleotide polymorphism) database, containing differential
expression ratio (DER) values for over 18,000 human protein
coding genes [3]. These DER values are calculated based on
mRNA gene expression studies in the GEO (gene expression
omnibus) database [4] and represent the ratio between the number
of studies in which a gene is found to be differentially expressed and
the number of studies in which the gene expression has been
evaluated. Genes with DER values higher than 0.55 appear to be
associated with the occurrence of disease associated variants [3].
Here, we hypothesize that the DER value of a gene can be used to
predict the presence of mutations in cancer genomes.
The second prioritization strategy is related to the fitSNP
approach and is based on the actual variance of the gene
expression levels within one tumor entity (calculated as the
standard deviation in one particular data set). This hypothesis is
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based on the idea that the variance in gene expression is caused by
one or more perturbation mechanisms, including gene mutations.
The correlation coefficient between gene expression levels and
gene copy numbers was evaluated as a third strategy, allowing the
identification of dosage sensitive genes. Our hypothesis states that
dosage sensitive genes are more prone to acquire mutations that
can deregulate their expression and function.
The final strategy is linked to the Knudson-two hit hypothesis
that states that tumor suppressor genes are biallelically inactivated
[5]. We therefore explored whether genes with a high frequency of
copy number loss (first hit) across the data set are more likely to
carry a mutation (second hit).
In this study, we specifically evaluated whether the top-ranked
genes in the prioritized gene lists are more likely to carry
somatically acquired mutations. Apart from candidate gene
ranking based on a single prioritization strategy, we also explored
if combinations could improve the original results. Publically
available data sets were used, consisting of copy number, gene
expression and mutational data for six different tumor types:
breast cancer, colon cancer, pancreas cancer, ovarian cancer,
glioblastoma and medulloblastoma. Table 1 provides an overview
of the different studies and number of samples available for the
different information layers.
Results
Comparison of the single prioritization strategies
The four single prioritization strategies are compared with each
other and with the baseline PPV for the six different tumor types
separately. The curves plotted in Figure 1 represent the number of
genes that have to be sequenced to obtain a certain number of
mutated genes. Curves below the baseline point at enrichment of
mutation genes in the top ranked genes and indicate a valuable
strategy for targeted resequencing.
The fitSNP curve for colon cancer clearly shows that
prioritizing based on fitSNP DER values leads to a huge
improvement in the discovery of mutated genes compared to a
random selection of genes (Figure 1A). When 100 top fitSNP genes
are sequenced, the PPV or mutation rate is increased by 2.3 fold
compared to the baseline PPV (11% compared to 4.7%) (Table
S1). This is also reflected in the number of genes that need to be
sequenced to find 10 mutated genes; more than double the
number of randomly selected genes (213) should be sequenced in
comparison with 93 top fitSNP genes. Although fitSNP clearly
outperforms the other prioritization strategies in colon cancer, the
other three also successfully prioritize mutated genes, even though
for the expression variance this improvement is only seen within
the top 100 genes (Figure S1A). The maximum PPV that could
be obtained for colon cancer is 50% for the top 4 fitSNP genes
(Table S1).
Also for pancreas cancer, fitSNP strategy outperforms the other
strategies and random selection (Figure 1B). For both the
expression variance and the frequency of copy number loss no
substantial improvement was noticed. Due to a lack of matching
gene expression and copy number data for pancreas cancer, no
dosage sensitivity values could be determined. The increase in
PPV starts with larger gene lists in pancreas cancer compared to
colon cancer and is already obvious for the top 250 genes. Eleven
mutated genes can be found when the top-100 fitSNP genes are
sequenced (PPV: 11%), compared to 6 genes with mutations for a
random selection of 100 candidate genes (PPV: 6.5%), which is an
almost 2-fold increase (Table S1). Within the top 7 of fitSNP
ranked genes a maximum PPV of 28.6% was obtained (Table S1,
Figure S1B).
Table 1. Overview of the publically available tumor data sets, used in this study.
Tumor entity Copy number data Gene expression data Combined CN and GE data Gene mutational data
Breast cancer 22 samples 15 samples 12 samples 10 primary breast ductal adenocarcinomas
GSE22840 (GSE22839) GSE22840 (GSE22544) 618000 genes sequenced
Sjo¨blom et al. [10], Wood et al. [11]
Colon cancer 38 samples 19 samples 19 samples 11 liver metastases from colorectal carcinomas
GSE17047 GSE17047 618000 genes sequenced
Sjo¨blom et al. [10], Wood et al. [11]
Ovarian cancer 9 samples 9 samples 9 samples 7 ovarian clear cell carcinomas*
GSE19539 GSE19539 618000 genes sequenced
Jones et al. [7]
Glioblastoma 15 samples 15 samples 15 samples 19 primary glioblastoma multiforme samples*
GSE10878 GSE10878 620000 genes sequenced
Parsons et al. [6]
Pancreas cancer 30 samples 36 samples / 24 primary/metastases pancreas
adenocarcinomas
GSE7599 GSE15471 620000 genes sequenced
Jones et al. [8]
Medulloblastoma 60 samples 77 samples / 14 pediatric classic medulloblastomas
GSE8634 GSE21140 621000 genes sequenced
Parsons et al. [9]
*one sample was excluded from this study due to a hypermutated profile caused by chemotherapeutic treatment.
CN: copy number; GE: gene expression.
doi:10.1371/journal.pone.0031333.t001
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For breast cancer the fitSNP strategy shows again an
improvement compared to the baseline values, however this
improvement is rather modest. For instance to find 10 mutated
genes, 164 random genes should be sequenced compared to 150
top fitSNP genes (Figure 1C, Table S1). The expression variance
strategy proves to be better than a random gene selection only
when the top-50 genes are sequenced. The gene dosage sensitivity
did not lead to any improvement in the results in this tumor type.
For the top-100 fitSNP genes and top-50 expression variance
genes a steep increase in PPV is present, with maximum PPV of
25% (top-4 genes) and 16% (top-6 genes) respectively (Table S1,
Figure S1C).
Since the baseline PPV for ovarian cancer is very low (0.73%),
more than 1300 random genes should have to be sequenced to
find 10 genes with a mutation (Figure 1D). However, when
focusing on the top fitSNP genes, only about half the number
needs to be sequenced (651), confirming that the fitSNP strategy is
also a valid strategy for this tumor type. To a lesser extent the gene
dosage could also increase the number of mutated genes found for
the same number of sequenced genes.
For the two remaining tumor types, glioblastoma and
medulloblastoma, the expression variance rather than the fitSNP
strategy seems to show the best results (Figure 1E, 1F). In
glioblastoma the expression variance is the best strategy to
improve mutation gene selection compared to the baseline,
although when looking at the top-100 ranked genes, an increase
in PPV can especially be seen for the fitSNP strategy (Figure S1E).
The baseline PPV in medulloblastoma could be improved using
all three strategies. For instance, to find 10 mutated genes in a
screen, more than 1600 random genes have to be sequenced,
which can be decreased to 321, 416 and 445 top genes for
expression variance, frequency of copy number loss and fitSNP
DER values, respectively. Looking at the PPV plot for medullo-
blastoma a rapid decrease can be seen for the top-ranked genes of
all strategies, indicating that none of the mutated genes can be
found in either of the top-ranked gene lists (Figure S1F).
Prioritizing using combined strategies
We occasionally observed substantial improvements in PPV
when combining different strategies (Table S1, Figure S2). One
clear example is breast cancer, where the mean PPV value reaches
26.9% for the top-25 genes when gene dosage sensitivity values
(0% PPV for top-25 using single method) and the frequency of
copy number loss (9.2% for top-25 using single method) are
combined (Table S1, Figure S2C).
Another example is medulloblastoma where none of the three
evaluated parameters had a PPV value higher than 0% for the top-
50. Combinations of fitSNP DER value and expression variance
or expression variance and frequency of copy number loss showed
a clear increase in PPV value in the top-ranked genes (Table S1,
Figure S2F).
For glioblastoma, fitSNP values in combination with expression
variance clearly performed best; to find 10 mutated genes 120 top
genes should be sequenced when the combined strategy is used,
compared to 259 or 157 genes for the fitSNP or expression
variance single strategies, respectively (Table S1, Figure S2E).
These results indicate that improvements in PPV value can be
obtained by using combinations of two different strategies.
However, for some combinations, an impairment rather than
improvement of the results was obtained, showing that combining
different prioritizing strategies does not per se result in better
candidate gene rankings.
Comparison of all strategies across the different tumor
entities
To compare the different prioritization methods across the six
tumor entities, a weighted ranking method was applied on the
mean of the PPV value of the 100 top-ranked genes, to produce a
ranked list of prioritization methods (Table S2, Figure S3). The
fitSNP DER value strategy in combination with the expression
variance, was ranked as the best overall method for the
prioritization of cancer genes for targeted resequencing, followed
by the fitSNP DER values alone. Similar results were seen using a
wide range of different cut-offs with respect to the number of top-
ranking genes taken into account (Table S2).
The gene dosage sensitivity value was ranked last and was the
only strategy that was ranked below the baseline value, indicating
that this strategy on itself is not useful to prioritize mutated genes
in the tested cancer entities. In contrast, when combined with
either the fitSNP or the frequency of copy number loss strategy,
the gene dosage sensitivity value was ranked third and fourth,
respectively.
Differences in mutational burden across the different
tumor types
When looking at the mutation frequency curves for the six
different tumor types (Figure 1A–F), we observe that for both
ovarian cancer and medulloblastoma the baseline PPV or
mutation rate is very low compared to the four other tumor
entities (Table S1). The baseline PPV of pancreas cancer (6.5%) is
more than 10 times higher than that of medulloblastoma (0.6%).
This means that to find 10 genes with mutations about 150
random genes would have to be sequenced in pancreas cancer, but
over 1500 in medulloblastoma (Figure 1C, 1F). The baseline PPV
for breast cancer, colon cancer and glioblastoma are more
comparable with pancreas cancer and lie between 4.1 and 6.1%,
whereas ovarian cancer has a baseline PPV of 0.7%.
Discussion
Given the current high costs of exome and whole genome
sequencing, we assessed whether targeted resequencing of
prioritized genes is a cost-efficient alternative to study a limited
but relevant subset of putative cancer genes. Four main
approaches to prioritize genes were evaluated: a gene’s fitSNP
DER value, the variance of gene expression levels within a tumor
type, the gene dosage sensitivity and the frequency of gene copy
number loss.
If a prioritization strategy is valid, the top-ranked genes in the
ordered gene list should be enriched for mutated genes. We
evaluated this enrichment by calculating the positive predictive
value (PPV), which represents the sequencing yield as the fraction
of mutated genes relative to the total number of genes analyzed. If
mutated genes are enriched in the top-ranked genes, the PPV will
increase for a smaller number of top-ranked genes. PPV values
were calculated for decreasing numbers of top-ranked genes, and
mean PPV values were calculated for a number of defined sizes of
top-ranked gene lists. Besides an increase in PPV in relation to
Figure 1. The number of mutated genes in relation to a certain number of top-ranked genes. Mutation plots showing the amount of
genes that need to be sequenced (y-axis) in order to find a certain number of mutated genes (depicted on the x-axis), for the six different tumor
types. A: colon cancer; B: pancreas cancer; C: breast cancer; D: ovarian cancer: E: glioblastoma; F: medulloblastoma.
doi:10.1371/journal.pone.0031333.g001
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smaller gene lists, a valid strategy should also require a high PPV
in comparison to the baseline, as this indicates that a high number
of mutated genes can be expected when performing a targeted
resequencing experiment.
Our results clearly demonstrate improvements in the mutation
rate of the selected genes when prioritization strategies are used
compared to the baseline level. These improvements are seen in
several tumor types and using different prioritization strategies,
with some variability between the different tumor types. This
variability indicates that there is no universal method to prioritize
genes across all tumor types, although the best improvements and
the largest overall PPV values were obtained for the fitSNP
strategy.
These between tumor entities differences are most likely
reflecting the reported diversity in mutational landscape in the
different tumor entities, as well as the specific mutational
background of the individual tumor genomes [6,7]. For instance,
we noticed a very small mutation frequency for the pediatric
cancer medulloblastoma, which is in concordance with the report
of Parsons et al. describing that this tumor displays a very different
mutational landscape compared to adult tumors [7]. Low
mutation frequencies are not confined to pediatric cancers only,
as in this specific study we found a mutation rate of only 0.7% in
ovarian clear cell carcinoma samples, which was remarkably lower
than in the other studied adult tumor types (4.1–6.5%).
In order to evaluate the different methods across all tumor data
sets, a weighted ranking method was used, pointing out that the
best overall performing strategy was based on fitSNP differentially
expressed ratio (DER) values. While it was previously hypothesized
by Chen and colleagues that cancer genes have higher fitSNP
DER values, the authors did not validate this by comparing fitSNP
values to the mutational status of the genes [3]. From our results,
we conclude that the cut-off for fitSNP DER values as determined
in the original study (i.e. 0.55 [3]), is not optimal to prioritize
mutated cancer genes, since for none of the tumors a substantial
increase in PPV could be found when using this threshold. We
suggest using a higher threshold of 0.65 for the prediction of
variants in cancer genes (as can be deduced from Figure 2 which
represents the overall PPV combining all tumor types).
The gene dosage sensitivity does not seem to have any
prioritization value, whereas the expression variance and frequency
of copy number loss were somewhat better than gene dosage
sensitivity but less good than fitSNP. Of note, the frequency of copy
number loss turned out to be not very useful in practice, since the low
number of cut-off values prevents to make distinct gene selections,
making the expression variance a preferred second best strategy.
By combining two different strategies, it was sometimes possible
to improve the results of the individual strategies. Although the
improvements could occasionally be huge, it again seemed to be
highly dependent on the data set reflecting the different mutational
mechanisms in different tumors. For instance, none of the three
prioritization methods evaluated were useful for medulloblastoma,
whereas combinations of two different parameters did successfully
prioritize genes.
While various cancer gene prioritization methods were shown to
be capable of increasing the yield of mutated cancer genes in the
different tested cancer entities, none of the methods specifically
enriched for genes that were mutated in more than one sample
(data not shown). This is probably due to the limited number of
cancer genomes studied within each entity and the fact that the
majority of the genes are found to be mutated in only one sample
(90 to 91%) (Table S3).
There are some limitations to this study that need to be
considered, for instance the sample size of some of the data sets
was rather limited, especially for the large genome sequencing
studies (7–24 samples per entity). However, it is at this point
difficult to find large cancer genome sequencing studies performed
on an adequate number of samples, confirming the starting
premise of our work that sequencing is currently cost prohibitive.
Due to the limited information that is presently available on
driver and passenger genes, we could not properly investigate
whether the fitSNP strategy is able to distinguish between driver and
passenger mutations. However, the top-10 fitSNP genes contain
30% of Cancer Gene Census genes [8], i.e. RUNX1, TRA@ and
NF1, whereas two other genes out of the top-10, CTNNA1 and
SMAD3, have an established role in cancer development as well
[9,10], illustrating that this strategy helps to identify genes with
proven role in carcinogenesis (Table S4, Figure S4).
In addition to the validity of the proposed strategy for targeted
resequencing, gene prioritization could also be an added value to
exome or whole genome sequencing. After such sequencing efforts
on a limited cohort, the variants that are found will most probably
have to be validated in a larger cohort. The fitSNP strategy might
be helpful for prioritization and filtering of cancer genes in such a
validation study.
Materials and Methods
Lists of mutated genes in cancer
Six large scale sequencing studies were used for the extraction of
mutational data on six different tumor entities (breast cancer,
colon cancer, pancreas cancer, ovarian cancer, glioblastoma,
medulloblastoma) [7,11–15] (Table 1). These data sets consist of
sequencing information on approximately 18,000 to 21,000 genes,
with a sample size ranging from 7 to 24, and were used to validate
the different prioritization strategies. Hypermutated samples, due
to chemotherapeutic treatment, as described in the respective
papers [11,13], were excluded from analysis.
Copy number and gene expression data sets
For the six tumor entities copy number and gene expression
data were downloaded from GEO [4]. We specifically selected
samples with a tumor histology corresponding to that of the
samples in the large scale sequencing screens as closely as possible
(Table 1). For pancreas cancer and medulloblastoma no matching
gene expression and copy number data were available. The
sample sizes in these studies ranged from 9 to 77.
Data analysis
For all copy number data sets, circular binary segmentation
(CBS) values [16] were determined and extracted for each gene
location. If no CBS value was available for a certain gene location,
the nearest value was assigned to the gene. These CBS values were
used to determine the frequency of copy number loss of each gene
in the tumor cohort, and were correlated with the gene expression
levels (Spearman rank correlation). For determination of copy
number loss, different cut-off settings were used, according to the
information provided in the original paper of the data set used
(Table S5). The expression variance for each gene within each
tumor type was calculated by the standard deviation of logged
expression levels.
Based on their corresponding prioritization value, either fitSNP
DER value [17], expression variance, gene dosage sensitivity or
frequency of copy number loss, genes were ranked in descending
order.
For the combined methods, the top-ranked gene lists were
determined by taking the intersection of the top-ranked genes as
defined by two single parameters.
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For each cancer entity, the number of mutated genes was plotted
(y-axis) in relation to a certain number of top-ranked genes that
should be sequenced (x-axis). For the single prioritization strategies
these curves were then compared with the baseline mutational level
in the tumor entity, which represents the ratio of mutated genes
versus the number of genes sequenced to obtain a certain number of
mutated genes if no prioritization strategy is used.
In addition, the positive predictive value (PPV), or the mutation
rate, was calculated for all different strategies. This value
represents the ratio between the number of genes with mutations
and the total number of genes in a certain gene subset. These
values were calculated for different cut-off levels of top-ranked
genes (500 - 400 - 300 - 200 - 150 - 100 - 75 - 50 - 25 - 10),
whereby the change in PPV compared to the baseline value was
evaluated.
In order to identify the best performing strategy across the
different tumor types, mean PPV values determined for several
top-ranked genes cut-offs, and the baseline PPV, (Table S1) were
analysed using brute force weighted ranking analysis. This analysis
yielded a ranked list of the different prioritization methods across
the different tumor types (Table S2). For the weighted ranking
analysis of the 10 different prioritization strategies (4 single
strategies and 6 combined strategies), the medulloblastoma and
pancreas cancer data sets were excluded, due to the absence of
gene dosage sensitivity values.
As an evaluation of the fitSNP cut-off determined by Chen et al.
[3], the mutational information on all different cancer types was
combined and the PPV was determined for different fitSNP cut-off
values (Figure 2).
For all analyses, the statistical platform R was used (packages
GEOquery, DNAcopy, RankAggreg) [18–20].
Supporting Information
Figure S1 Overview of PPV plots in function of the
number of sequenced genes for the six cancer entities.
(TIF)
Figure S2 Visualization of the weighted ranking results
for the top-100 ranked genes. The grey lines represent the
ranking of the four different tumor types for the 10 prioritization
strategies (4 single strategies and 6 combined strategies) and the
baseline level. In red, the result of the brute force ranking
algorithm is shown. The black line is where the baseline level is
ranked across the different data sets. EV: expression variance; DS:
dosage sensitivity; FCNL: frequency of copy number loss
(TIF)
Figure S3 Plots of the number of mutated genes in
relation to a certain number of top-ranked genes for the
six cancer entities, including the combination strategies.
(TIF)
Figure S4 Plots of the percentage of mutated fitSNP
genes that are found to be drivers. For colon cancer,
glioblastoma, pancreas cancer and breast cancer, the PPV is
plotted for the top 500 fitSNP genes (black line). The grey line
represents the percentage of mutated fitSNP genes that are
identified as driver genes according to the respective publications.
Enrichment of identified driver genes can be seen in the top fitSNP
Figure 2. PPV plot of the fitSNP strategy for the combined tumor entities. A PPV plot for the fitSNP strategy, performed on the mutation
data of all combined tumor entities, in function of different prioritization value cut-offs.
doi:10.1371/journal.pone.0031333.g002
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genes in both colon cancer and glioblastoma, whereas in pancreas
cancer and breast cancer this could not be confirmed.
(PDF)
Table S1 Overview of the analyses per cancer entity and
prioritization strategy. Overview listing the PPV, number of
sequenced genes and number of mutated genes for the baseline
PPV, maximum PPV, a different number of top-ranked genes and
1 to 20 mutated genes. In red, values are indicated that don’t
match with the number of top-ranked genes considered, due to
cut-off restrictions of the prioritization method.
(XLS)
Table S2 Ranked lists of the different prioritization
methods. These ranked lists are based on the brute force
weighted ranking algorithm, performed across the different cancer
entities. The ranking has been performed on the single
prioritization strategies alone as well as together with the
combined strategies.
(XLS)
Table S3 Overview of the mutated genes in the different
studied cancer entities.
(XLS)
Table S4 Overview of the mutated genes in the top-500
fitSNP genes.
(XLSX)
Table S5 Cut-offs used for the different cancer entities
to determine copy number loss.
(XLS)
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